Biora Therapeutics, Inc. (BIOR)
NASDAQ: BIOR · IEX Real-Time Price · USD
0.730
-0.008 (-1.03%)
At close: May 17, 2024, 4:00 PM
0.749
+0.019 (2.63%)
After-hours: May 17, 2024, 7:53 PM EDT
Biora Therapeutics Revenue
Biora Therapeutics had revenue of $544.00K in the twelve months ending March 31, 2024, with 172.00% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $542.00K with 27,000.00% year-over-year growth. In the year 2023, Biora Therapeutics had annual revenue of $4.00K, a decrease of -98.69%.
Revenue (ttm)
$544.00K
Revenue Growth
+172.00%
P/S Ratio
48.61
Revenue / Employee
$9,379
Employees
58
Market Cap
26.44M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.00K | -301.00K | -98.69% |
Dec 31, 2022 | 305.00K | -942.00K | -75.54% |
Dec 31, 2021 | 1.25M | 1.09M | 669.75% |
Dec 31, 2020 | 162.00K | -143.82M | -99.89% |
Dec 31, 2019 | 143.99M | 16.01M | 12.51% |
Dec 31, 2018 | 127.97M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBIOR News
- 3 days ago - Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 11 days ago - Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewsWire
- 12 days ago - Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024 - GlobeNewsWire
- 18 days ago - Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600 - GlobeNewsWire
- 5 weeks ago - Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology - GlobeNewsWire
- 6 weeks ago - Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development - GlobeNewsWire
- 6 weeks ago - Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire